Existing and emerging therapies for irritable bowel syndrome

Abstract

Introduction: Irritable bowel syndrome is a common disorder that is associated with a significant impact on both affected individuals and society. While the pathophysiology of irritable bowel syndrome remains unknown, knowledge regarding the normal and abnormal functions of the gut and its complex interaction with the body's nervous systems continues to shed light on the multifactorial origins of irritable bowel syndrome symptoms. This article provides an overview of the current knowledge of the therapeutic approaches to irritable bowel syndrome.

Areas covered: A search of the online bibliographic databases MEDLINE and EMBASE was performed in order to identify all relevant articles published between 1980 and 2010. The search was enhanced with the use of a medical librarian. Bibliographies from potentially relevant articles were manually searched.

Expert opinion: The therapeutic options for irritable bowel syndrome are rapidly evolving beyond traditional symptom-based therapies, such as fiber, antispasmodics, antidiarrheals and laxatives, and are moving toward agents with organ-specific receptor selectivity directed, in many cases, at specific gastrointestinal functions.

Keywords::

• alosetron
• irritable bowel syndrome
• linaclotide
• lubiprostone
• rifaximin
• talnetant
• tegaserod

Declaration of interest

The opinions and assertions contained herein are the sole views of the authors and should not be construed as official or as representing the views of the US Navy, Department of Defense or Department of Veteran Affairs. BD Cash is a speaker and/or consultant for Salix, Prometheus, Ironwood and Takeda.